Health Care Utilization and Costs After Initiating Budesonide/Formoterol Combination or Fluticasone/Salmeterol Combination Among COPD Patients New to ICS/LABA Treatment

BACKGROUND: Chronic obstructive pulmonary disease (COPD) affects approximately 15 million people in the United States and accounts for approximately $36 billion in economic burden, primarily due to medical costs. To address the increasing clinical and economic burden, the Global Initiative for Chron...

Descripción completa

Detalles Bibliográficos
Autores principales: Davis, Jill R., Kern, David M., Williams, Setareh A., Tunceli, Ozgur, Wu, Bingcao, Hollis, Sally, Strange, Charlie, Trudo, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397958/
https://www.ncbi.nlm.nih.gov/pubmed/27003559
http://dx.doi.org/10.18553/jmcp.2016.22.3.293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397958/
https://www.ncbi.nlm.nih.gov/pubmed/27003559
http://dx.doi.org/10.18553/jmcp.2016.22.3.293

Ejemplares similares